Jardiance mechanism of action
Pro Research Analysisby 
Searched over 200M research papers
Jardiance (Empagliflozin) Mechanism of Action: SGLT2 Inhibition in Type 2 Diabetes
Empagliflozin, marketed as Jardiance, is a sodium-glucose cotransporter-2 (SGLT2) inhibitor used to treat adults with type 2 diabetes mellitus. Its primary mechanism of action is to block SGLT2 proteins in the proximal tubules of the kidneys. This inhibition reduces the reabsorption of glucose back into the bloodstream, leading to increased glucose excretion in the urine and, consequently, lower blood glucose levels. This process is independent of insulin, making empagliflozin effective even when insulin function is impaired or insufficient Scott2014Shafiq2022Frampton2018+1 MORE.
Insulin-Independent Glucose Lowering and Additional Metabolic Effects
Because empagliflozin works independently of insulin, it carries a low risk of causing hypoglycemia when used alone. It can be used as monotherapy or in combination with other antidiabetic agents, including insulin, to improve glycemic control. In addition to lowering blood sugar, empagliflozin has been shown to modestly reduce body weight and systolic blood pressure in patients with type 2 diabetes Scott2014Frampton2018.
Cardiorenal Protective Effects of Jardiance
Beyond its glucose-lowering effects, empagliflozin has demonstrated significant benefits for heart and kidney health. Clinical studies have shown that empagliflozin reduces the risk of cardiovascular death and hospitalization for heart failure in adults with type 2 diabetes and established cardiovascular disease. These protective effects are thought to be largely independent of its impact on blood sugar levels Shafiq2022Frampton2018Gamito2024.
Impact on Cardiac Sodium and Calcium Regulation
Research in diabetic animal models suggests that empagliflozin may also help regulate sodium and calcium levels in heart cells. This can improve cardiac electrical activity and reduce harmful changes in heart structure and function, which may contribute to its observed cardioprotective benefits in patients with diabetes .
Conclusion
Jardiance (empagliflozin) lowers blood glucose by inhibiting SGLT2 in the kidneys, leading to increased urinary glucose excretion. Its insulin-independent action, combined with additional benefits for weight, blood pressure, and heart and kidney health, makes it a valuable option for managing type 2 diabetes, especially in patients at high cardiovascular risk Scott2014Shafiq2022Frampton2018+2 MORE.
Sources and full results
Most relevant research papers on this topic